Jonathan D Edgeworth
Overview
Explore the profile of Jonathan D Edgeworth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alcolea-Medina A, Alder C, Snell L, Charalampous T, Aydin A, Nebbia G, et al.
Commun Med (Lond)
. 2024 Jul;
4(1):151.
PMID: 39060434
No abstract available.
2.
Alcolea-Medina A, Alder C, Snell L, Charalampous T, Aydin A, Nebbia G, et al.
Commun Med (Lond)
. 2024 Jul;
4(1):135.
PMID: 38972920
Background: Clinical metagenomics involves the genomic sequencing of all microorganisms in clinical samples ideally after depletion of human DNA to increase sensitivity and reduce turnaround times. Current human DNA depletion...
3.
Alcolea-Medina A, Snell L, Payne L, Alder C, Turnbull J, Charalampous T, et al.
Int J Syst Evol Microbiol
. 2023 Dec;
73(12).
PMID: 38050797
A novel bacterial strain, GSTT-20 was isolated from an infected, prosthetic endovascular graft explanted from a shepherd in London, United Kingdom. This strain was an aerobic, catalase-positive, oxidase-negative, Gram-stain-negative, motile,...
4.
Charalampous T, Alcolea-Medina A, Snell L, Alder C, Tan M, Williams T, et al.
Am J Respir Crit Care Med
. 2023 Nov;
209(2):164-174.
PMID: 37938162
Respiratory metagenomics (RMg) needs evaluation in a pilot service setting to determine utility and inform implementation into routine clinical practice. Feasibility, performance, and clinical impacts on antimicrobial prescribing and infection...
5.
Williams T, Snell L, Alder C, Charalampous T, Alcolea-Medina A, Sehmi J, et al.
Microb Genom
. 2023 Aug;
9(8).
PMID: 37590039
Rapid respiratory viral whole genome sequencing (WGS) in a clinical setting can inform real-time outbreak and patient treatment decisions, but the feasibility and clinical utility of influenza A virus (IAV)...
6.
Alcolea-Medina A, Snell L, Alder C, Charalampous T, Williams T, Tan M, et al.
Clin Microbiol Infect
. 2023 Mar;
29(7):887-890.
PMID: 36925107
Objectives: Epidemiological and whole-genome sequencing analysis of an ongoing outbreak of Streptococcus pyogenes (Group A Streptococcus) in London (United Kingdom). Methods: Prospective identification of Group A Streptococcus cases from a...
7.
Edgeworth J
Curr Opin Infect Dis
. 2023 Feb;
36(2):115-123.
PMID: 36853748
Purpose Of Review: The coronavirus disease 2019 pandemic demonstrated broad utility of pathogen sequencing with rapid methodological progress alongside global distribution of sequencing infrastructure. This review considers implications for now...
8.
Kurshan A, Snell L, Prior L, Tam J, Graham C, Thangarajah R, et al.
Oxf Open Immunol
. 2023 Feb;
4(1):iqac012.
PMID: 36844257
Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce...
9.
Snell L, Alcolea-Medina A, Charalampous T, Alder C, Williams T, Flaviani F, et al.
Clin Infect Dis
. 2022 Nov;
76(6):1125-1128.
PMID: 36327795
The management of coronavirus disease 2019 has become more complex due to the expansion of available therapies. The presence of severe acute respiratory syndrome coronavirus 2 variants and mutations further...
10.
Wang W, Snell L, Ferrari D, Goodman A, Price N, Wolfe C, et al.
BMC Infect Dis
. 2022 Oct;
22(1):776.
PMID: 36199017
Introduction: Randomised controlled trials have shown that steroids reduce the risk of dying in patients with severe Coronavirus disease 2019 (COVID-19), whilst many real-world studies have failed to replicate this...